Niagen Bioscience, Inc.

7.27-0.33 (-4.34%)

Oct 28, 4:00:00 PM EDT · NasdaqCM · NAGE · USD

Upcoming Earnings

Report date

Nov 4, 2025 (in 6 days)

Key Stats

Market Cap

579.80M

P/E (TTM)

33.05

Basic EPS (TTM)

0.22

Dividend Yield

Recent Filings

8-K

Raises 2025 sales outlook

10/6/25Oct 6, 2025

Niagen Bioscience raised its full-year 2025 net sales outlook to 25% to 30% year-over-year growth, up from 22% to 27%, citing the FDA's reversal on NMN rulings that boosts NAD+ precursor awareness. The company highlights Niagen's superiority over NMN in bioavailability and quality, while noting widespread IP infringement by NMN products. Regulatory shifts minimally impact its differentiated business. Forward-looking statements carry risks like legal actions over patents.

8-K

Q2 sales up 37%, outlook raised

8/6/25Aug 6, 2025

Niagen Bioscience reported Q2 2025 net sales of $31.1 million, up 37% year-over-year, with gross margins expanding 480 basis points to 65.0% and net income hitting $3.6 million versus breakeven last year. The company raised its full-year revenue outlook to 22%-27% growth, fueled by e-commerce strength and Niagen ingredient demand, while advancing clinical efforts like a Parkinson's license and Werner syndrome study. Cash swelled to $60.5 million. Profitability surges amid R&D investments.

10-Q

Q2 FY2025 results

8/6/25Aug 6, 2025

Niagen Bioscience swung to profitability in Q2 FY2025 ended June 30, 2025, with net sales climbing 37% year-over-year to $31.1M, fueled by 22% growth in consumer products to $22.7M and a 131% surge in ingredients to $7.6M, while gross margins expanded from 60.2% to 65.0% on better mix and efficiencies. Operating income hit $3.2M, up from a $0.3M loss, with diluted EPS of $0.04 versus breakeven last year; year-to-date, sales rose 37% to $61.6M and net income reached $8.7M or $0.10 per share, reconciling to 84.9M diluted shares. Cash swelled to $60.5M on $9.1M operating inflows minus $0.2M capex, yielding $8.9M free cash flow, with no debt but $32.6M in committed inventory buys through mid-2026 under a new exclusive supply pact with W.R. Grace. A July 2025 lease amendment added $1.1M to right-of-use assets, extending to 2030. Yet customer concentration risks linger, as four clients hold 71.7% of $9.7M receivables.

8-K

Exclusive NRCL supply deal signed

7/29/25Jul 29, 2025

Niagen Bioscience's subsidiary ChromaDex signed a supply agreement with W.R. Grace on July 25, 2025, effective April 1, 2025, for exclusive provision of Nicotinamide-beta-Riboside Chloride through April 30, 2029, with auto-renewal. Grace can't sell to others and must notify ChromaDex of inquiries, while ChromaDex commits to minimum annual purchases and binding 12-month forecasts. This secures supply continuity, with a potential royalty-bearing license if the deal ends under specific triggers like breach or market exit. Yet risks loom if volumes falter.

8-K

Stock plans approved, shares expanded

6/27/25Jun 27, 2025

Niagen Bioscience stockholders approved an amendment to the 2017 Equity Incentive Plan, adding 4.75 million shares for employee incentives, and launched the Employee Stock Purchase Plan with 650,000 shares at an 85% market discount. This bolsters talent retention amid bioscience growth pressures. Yet dilution looms for existing holders.

About

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

CEO

Mr. Frank Louis Jaksch Jr.

IPO

6/25/2008

Website

https://www.niagenbioscience.com

Employees

104

Sector

Healthcare

Industry

Biotechnology